Jackson Center, PA, February 1, 2021 – Halberd Corporation’s (OTC PINK:HALB) Chairman, President & CEO, William A. Hartman, was interviewed recently on The Stock Day Podcast, hosted by Everett Jolly, and on MoneyTV, hosted by Don Baillargeon. In each interview, Mr. Hartman reviewed the company’s progress on developing SARS-CoV-2 spike protein antibodies which could be used in diagnosing, preventing and treating COVID-19. To view the entire MoneyTV Interview, click here.
Hartman commented on Halberd’s latest development, “We developed a patent pending fluorescent antibody which has demonstrated capability to detect not only the presence of the SARS-CoV-2 antigens, but the degree of infection (viral load) present in a sample. This may provide important feedback information to health care providers on the patient’s need for a vaccine or other treatment. With this information, it would permit the healthcare provider to adjust the medications or dosages, as appropriate.”
Mr. Hartman also provided a glimpse into the company’s latest research efforts using a metallic moiety (a metal nano-particle coupled with a monoclonal antibody) in conjunction with radio frequency energy to extracorporeally treat infected patients. This method has the potential to treat not only COVID-19, but can be tailored to treat COVID-19 variants, or any other blood-borne or cerebral spinal fluid (CSF)-borne infectious disease. Hartman continued, “We think this is a very big potential development and intend to pursue it vigorously. More information will be provided in very near future.
“In addition to Halberd’s monoclonal antibody based research and development, the company is developing nutraceutical vitamin formulations designed specifically to boost the immune system against SARS-CoV-2 and its variants. These formulations would benefit the entire population, both those who have received the vaccine and those who have not yet been vaccinated. Halberd is working with manufacturers and distributors to bring these products to market as quickly as possible.
“The company continues to maintain its focus on developing Intellectual property & technology targeting COVID-19 detection, prevention and treatment, with seven provisional patent applications filed and two issued patents.”
To listen to the Uptick Everett Jolly podcast, click here.
To be added to Halberd’s email subscriber list, click here and submit the form.
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About The “Stock Day” Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.
About MoneyTV
MoneyTV is, an internationally-syndicated weekly business television program reaching more than 180 million TV households globally. MoneyTV debuted in 1996, recently began its 22nd year on television and produced and broadcasted its 1,000th original episode in 2017. Its host, Don Baillargeon is the Founder, Executive Producer and Anchor of Money TV and a broadcast industry veteran of more than 30 years, running corporate radio stations at age 27 and having personally owned and operated KCHT-FM in California. He was the co-founder of one of the largest Advertising Agencies in central California. Money TV is based in San Clemente, California.
About Halberd Corporation
Halberd Corporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd’s Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company’s Articles of Incorporation here.
The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus,” “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans,” “Nasal Spray to Prevent the Transmission of Covid-19,” “Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus,” and “Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus).” Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.